| 1 |
NCT02410434 |
Completed |
Reducing Lesbian, Gay , Bisexual and Transgender (LGBT) Stigma in Swaziland and Lesotho |
|
- Other: LGBT Stigma Reduction Intervention
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Attitudes towards lesbian and gay men scale
- HIV-related stigma
- Civic participation
|
106 |
All |
18 Years and older (Adult, Senior) |
NCT02410434 |
#30344 |
|
February 2015 |
June 2015 |
June 2015 |
April 7, 2015 |
April 13, 2016 |
|
- Maluti School of Nursing
Maseru, Lesotho - Southern Africa Nazarene University
Manzini, Swaziland
|
| 2 |
NCT03012932 |
Recruiting |
HPV Self-Sampling for Cervical Cancer Screening Among Lesbian, Bisexual, and Queer (LBQ) Women |
- Cervical Cancer Screening
|
- Behavioral: HPV self-sampling
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
|
30 |
Female |
25 Years to 65 Years (Adult) |
NCT03012932 |
20161052 |
|
February 2, 2017 |
June 2018 |
August 2018 |
January 6, 2017 |
December 20, 2017 |
|
- University of Miami
Miami, Florida, United States
|
| 3 |
NCT02067845 |
Completed |
A Group-level Intervention to Reduce HIV/STI Risk for Women Who Have Sex With Women in Calgary and Toronto |
|
- Behavioral: Adapted Many Men, Many Voices (3MV) group level intervention
- Behavioral: A group-based HIV/STI prevention intervention for women who have sex with women
|
Interventional |
Not Applicable |
- University of Toronto
- The CIHR Social Research Centre in HIV Prevention
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- STI knowledge
- Safer sex self-efficacy
- STI and HIV incidence
- (and 8 more...)
|
44 |
Female |
18 Years and older (Adult, Senior) |
NCT02067845 |
CIHR SRC - 4487453 |
|
February 2014 |
June 2014 |
June 2014 |
February 20, 2014 |
January 6, 2015 |
|
- Faculty of Social Work, University of Calgary
Calgary, Alberta, Canada - University of Toronto, Factor-Inwentash Faculty of Social Work
Toronto, Ontario, Canada
|
| 4 |
NCT00634218 |
Completed |
Reaching and Treating Lesbian, Gay, Bisexual, and Transgender (LGBT) Cigarette Smokers |
|
- Behavioral: Mail-based Self-help plus Internet-based Smoking Treatment
- Behavioral: Self-Help Manual plus Telephone counseling
- Behavioral: Self-Help Manual
- Behavioral: Self-Help Manual plus Internet-based Intervention plus Telephone Counseling
|
Interventional |
Phase 2
Phase 3 |
- University of California, San Francisco
- Tobacco Related Disease Research Program
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
363 |
All |
18 Years and older (Adult, Senior) |
NCT00634218 |
TRDRP 15RT-0165 |
|
February 2008 |
January 2012 |
January 2012 |
March 12, 2008 |
June 27, 2012 |
|
- Univeristy of California, San Francisco
San Francisco, California, United States
|
| 5 |
NCT02875535 |
Enrolling by invitation |
Reducing LGBTQ Adolescent Suicide |
|
|
Interventional |
Not Applicable |
- Pacific Institute for Research and Evaluation
- University of New Mexico
- University of California, San Diego
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Adherence to EB strategy implementation
- Reduced suicidality and depression measured by the New Mexico Youth Risk and Resiliency Study (NM-YRRS)
- Substance Use measured by the NM-YRRS
- Feelings of safety measured by the NM-YRRS
|
40 |
All |
16 Years and older (Child, Adult, Senior) |
NCT02875535 |
0838.01.01 |
RLAS |
May 2016 |
December 2020 |
April 2021 |
August 23, 2016 |
September 23, 2016 |
|
|
| 6 |
NCT02459769 |
Recruiting |
Exercise Intervention for LGBT Cancer Survivors |
|
- Behavioral: Exercise for Cancer Patients
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Self-Reported Psychological Distress
- Biological Endpoints: Cortisol
- Biological Endpoints: Serum amyloid A
- (and 3 more...)
|
140 |
All |
21 Years and older (Adult, Senior) |
NCT02459769 |
56965 |
|
August 2015 |
May 2019 |
May 2019 |
June 2, 2015 |
February 12, 2018 |
|
- University of Rochester
Rochester, New York, United States
|
| 7 |
NCT00058669 |
Completed |
CVD Risk Factors and Sexual Identity in Women |
- Cardiovascular Diseases
- Heart Diseases
- Coronary Disease
|
|
Observational |
|
- University of Pittsburgh
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- risk of cardiovascular disease
|
1174 |
Female |
35 Years and older (Adult, Senior) |
NCT00058669 |
1210
R01HL067052 |
|
March 2003 |
February 2008 |
February 2008 |
April 11, 2003 |
January 5, 2016 |
|
|
| 8 |
NCT02986126 |
Recruiting |
Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities) |
|
- Behavioral: Resiliency Class
- Other: Resource for Services (RS)
|
Interventional |
Not Applicable |
- Bowen Chung, MD, MSHS
- Louisiana State University Health Sciences Center in New Orleans
- Tulane University
- (and 5 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Depressive symptom count as measured by the Patient Health Questionnaire 8
- Poor Mental Health-Related Quality of Life
- Resilience
- (and 2 more...)
|
320 |
All |
18 Years and older (Adult, Senior) |
NCT02986126 |
PPRND-1507-32173 |
RADD |
May 4, 2017 |
August 30, 2019 |
October 31, 2019 |
December 8, 2016 |
December 22, 2017 |
|
- R.O.A.D.S. Clinic
Compton, California, United States - The ADAM Project - YMSM Program
Long Beach, California, United States - The LGBTQ Center - Long Beach
Long Beach, California, United States - (and 12 more...)
|
| 9 |
NCT00001294 |
Completed |
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens |
- Alcoholism
- HIV Infection
- Homosexuality
- Kaposi's Sarcoma
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
2000 |
All |
Child, Adult, Senior |
NCT00001294 |
920078
92-C-0078 |
|
January 1992 |
|
April 2005 |
November 4, 1999 |
March 4, 2008 |
|
- National Cancer Institute (NCI)
Bethesda, Maryland, United States
|
| 10 |
NCT01633567 |
Completed |
Culturally Targeted & Individually Tailored Smoking Cessation Study: LGBT Smokers |
|
- Behavioral: Culturally Targeted Cessation Program
- Behavioral: Non-Targeted Cessation Program
|
Interventional |
Not Applicable |
- University of Illinois at Chicago
- National Institute on Drug Abuse (NIDA)
- National Cancer Institute (NCI)
- Howard Brown Health Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 7-Day Point Prevalence Smoking Quit Rates 1 Month Post Quit Date
- 7-Day Point Prevalence Smoking Quit Rates 3 Months Post Quit Date
- 7-Day Point Prevalence Smoking Quit Rates 6 Months Post Quit Date
- 7-Day Point Prevalence Smoking Quit Rates 12 Months Post Quit Date
|
400 |
All |
18 Years to 65 Years (Adult) |
NCT01633567 |
2010-0538
R01DA023935 |
|
May 2012 |
January 2016 |
January 2016 |
July 4, 2012 |
May 4, 2017 |
|
- Howard Brown Health Center
Chicago, Illinois, United States
|
| 11 |
NCT00111501 |
Completed |
LGBT Internet Based Smoking Treatment - 1 |
|
- Behavioral: Tobacco Use Disorder
- Behavioral: Standard Web-based intervention
|
Interventional |
Phase 3 |
- University of California, San Francisco
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- point-prevalence abstinence from tobacco use
|
792 |
All |
18 Years and older (Adult, Senior) |
NCT00111501 |
NIDA-15791-1
R01DA015791
R01-15791-1 |
|
September 2002 |
January 2009 |
January 2009 |
May 23, 2005 |
March 6, 2015 |
|
- University of California San Francisco Medical Cen
San Francisco, California, United States
|
| 12 |
NCT00374387 |
Completed |
Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire |
|
- Drug: Nuvaring
- Drug: low-dose combination pill
- Drug: minipill
|
Interventional |
Not Applicable |
- University Hospital, Ghent
- Fund for Scientific Research, Flanders, Belgium
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Parameters about sexual desire and psychosocial, relational en sexual parameters.
|
150 |
Female |
18 Years to 45 Years (Adult) |
NCT00374387 |
2006/309 |
|
September 2006 |
August 2009 |
March 2011 |
September 11, 2006 |
March 31, 2011 |
|
- University Hospital Ghent
Ghent, Belgium
|
| 13 |
NCT02921841 |
Enrolling by invitation |
Digital Star: HIV Prevention for Youth in Mental Health Treatment |
- Human Immunodeficiency Virus
- Mental Health
|
- Behavioral: D*STAR
- Behavioral: D*HEALTH
|
Interventional |
Not Applicable |
- Rhode Island Hospital
- Virtually Better, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Safer Sexual Behaviors
- Greater HIV knowledge/attitudes
- Greater Self-efficacy for HIV prevention skills
- (and 5 more...)
|
120 |
All |
13 Years to 20 Years (Child, Adult) |
NCT02921841 |
R44MH102140 |
DSTAR |
November 2016 |
July 2018 |
July 2018 |
October 3, 2016 |
September 15, 2017 |
|
- Rhode Island Hospital
Providence, Rhode Island, United States
|
| 14 |
NCT03191474 |
Recruiting |
Linkage of Transgender Individuals to PrEP |
- HIV Seronegativity
- Linkage
|
- Behavioral: T-POWr Intervention
|
Interventional |
Not Applicable |
- California Collaborative Treatment Group
- University of Southern California
- LA Biomed at Harbor-UCLA
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03191474 |
CCTG 602 |
|
July 28, 2017 |
April 6, 2020 |
April 6, 2021 |
June 19, 2017 |
August 21, 2017 |
|
- Los Angeles Lesbian, Gay, Bisexual, and Transgender Center
Los Angeles, California, United States - University of California, San Diego
San Diego, California, United States
|
| 15 |
NCT03029962 |
Recruiting |
Girl2Girl: Harnessing Text Messaging to Reduce Teenage Pregnancy Among LGB Girls |
|
|
Interventional |
Not Applicable |
- Center for Innovative Public Health Research
- The Office of Adolescent Health, HHS
- University of British Columbia
- City University of New York, School of Public Health
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Number of participants who used other birth control methods
- Number of protected penile-vaginal sex acts
- Number of participants who abstained from penile-vaginal and penile-anal sex
- Number of penile-vaginal sex acts during which a condom was used
|
840 |
Female |
14 Years to 18 Years (Child, Adult) |
NCT03029962 |
1 TP2AH000035-01-00 |
Girl2Girl |
October 2016 |
July 2019 |
July 2019 |
January 24, 2017 |
September 13, 2017 |
|
- Center for Innovative Public Health Research
San Clemente, California, United States
|
| 16 |
NCT01201083 |
Unknown † |
Study of Recently HIV Infected Men and Transmission Behaviors |
|
|
Observational |
|
- University of California, Los Angeles
- Los Angeles Biomedical Research Institute
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To measure how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners
|
600 |
Male |
18 Years and older (Adult, Senior) |
NCT01201083 |
R01DA022116 - A1
G07-06-117-03
R01DA022116 |
MetroMates |
February 2009 |
August 2013 |
August 2013 |
September 14, 2010 |
September 14, 2010 |
|
- Los Angeles Gay and Lesbian Center
Los Angeles, California, United States
|
| 17 |
NCT02113956 |
Completed |
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior |
|
- Behavioral: Guy2Guy (G2G)
|
Interventional |
Not Applicable |
- Center for Innovative Public Health Research
- Northwestern University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Unprotected sex acts
- Abstinence
- Unprotected sex acts by sexual experience group
- (and 3 more...)
|
302 |
Male |
14 Years to 18 Years (Child, Adult) |
NCT02113956 |
Pro00007481
1R01MH096660-01A1 |
G2G |
June 2014 |
June 2015 |
June 2015 |
April 15, 2014 |
August 31, 2016 |
|
- Center for Innovative Public Health Research
San Clemente, California, United States - Northwestern University
Chicago, Illinois, United States
|
| 18 |
NCT01781806 |
Completed
Has Results |
A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services |
|
- Drug: emtricitabine 200mg/tenofovir 300mg
|
Interventional |
Phase 4 |
- University of California, Los Angeles
- Los Angeles County Department of Public Health
- Los Angeles LGBT Center
- (and 2 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of Participants With a Grade 2 or Higher Adverse Event by Cohort
- Cohort H PrEP Engagement by Study Visit
|
328 |
Male |
18 Years and older (Adult, Senior) |
NCT01781806 |
EI11-LA-002 |
PATH-PrEP |
May 2013 |
May 2016 |
May 2016 |
February 1, 2013 |
April 6, 2018 |
September 20, 2017 |
- L.A. Gay and Lesbian Center
Los Angeles, California, United States - The OASIS Clinic
Los Angeles, California, United States
|
| 19 |
NCT00949234 |
Completed
Has Results |
Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV |
- HIV Prevention
- HIV Infections
|
- Drug: tenofovir + emtricitabine, lopinavir/ritonavir
|
Interventional |
Phase 2 |
- University of California, Los Angeles
- Los Angeles County Department of Public Health
- AIDS Project Los Angeles
- (and 2 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit
|
267 |
All |
18 Years and older (Adult, Senior) |
NCT00949234 |
PQUAD |
|
March 2010 |
June 2010 |
August 2011 |
July 30, 2009 |
December 18, 2017 |
December 18, 2017 |
- L.A. Gay & Lesbian Center
Los Angeles, California, United States - OASIS Clinic
Los Angeles, California, United States
|
| 20 |
NCT01015690 |
Completed |
Incidence of Early Pregnancy Loss in Patients With Unexplained Infertility |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- incidence of early pregnancy loss
- incidence of pregnancies
|
134 |
Female |
18 Years to 40 Years (Adult) |
NCT01015690 |
UNEXPLAINED |
UNEXPLAINED |
June 2006 |
March 2009 |
March 2009 |
November 18, 2009 |
November 18, 2009 |
|
- UMCUtrecht
Utrecht, Netherlands
|
| 21 |
NCT01335360 |
Completed |
Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight |
|
|
Observational |
|
- Western University of Health Sciences
- Jeffrey Goodman Clinic, LA Gay & Lesbian Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Differences in AUC based on weight/BMI
|
21 |
Male |
18 Years to 50 Years (Adult) |
NCT01335360 |
WesternU |
NAWS |
May 2003 |
May 2003 |
June 2003 |
April 14, 2011 |
April 14, 2011 |
|
- Jeffrey Goodman Clinic
Los Angeles, California, United States
|
| 22 |
NCT02816879 |
Recruiting |
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men |
- Anal Carcinoma
- HIV Infection
- Human Papillomavirus Infection
|
- Procedure: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Interventional |
Not Applicable |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Accuracy of cytology specimens for Dacron swab compared to flocked nylon (NF) swab in predicting histology outcome
- Ability of APTIMA-HPV to predict risk for HG-AIN
- Ability of Hybrid-capture 2 to predict risk for HG-AIN
- Cost effectiveness analysis evaluating differences in survival, the cost of out-patient procedures & in-patient hospitalizations for invasive anal cancer.
|
375 |
Male |
18 Years and older (Adult, Senior) |
NCT02816879 |
RCA169508A
NCI-2014-01292
JCCCID370
P30CA016042
R01CA169508
13-000997 |
|
July 9, 2013 |
July 31, 2018 |
July 31, 2019 |
June 29, 2016 |
September 13, 2017 |
|
- Los Angeles Gay and Lesbian Center
Los Angeles, California, United States - UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - Desert AIDS Project
Palm Springs, California, United States
|
| 23 |
NCT03086200 |
Recruiting |
CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study) |
- Patient Adherence
- HIV Seronegativity
|
- Behavioral: brief Motivational Interviewing
|
Interventional |
Not Applicable |
- California Collaborative Treatment Group
- University of Southern California
- LA Biomed at Harbor-UCLA
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT03086200 |
CCTG 603 |
|
June 23, 2017 |
April 6, 2020 |
April 6, 2021 |
March 22, 2017 |
October 11, 2017 |
|
- Los Angeles Lesbian, Gay, Bisexual, and Transgender Center
Los Angeles, California, United States - University of Southern California
Los Angeles, California, United States - Family Health Centers of San Diego
San Diego, California, United States - (and 2 more...)
|
| 24 |
NCT02624193 |
Active, not recruiting |
Health Improvement for Baltimore Youth |
- HIV
- Adolescent Development
- Adolescent Behavior
- Medication Adherence
|
- Behavioral: MBSR Program
- Behavioral: HT Program
|
Interventional |
Not Applicable |
- Johns Hopkins University
- National Center for Complementary and Integrative Health (NCCIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Treatment Adherence
- NIH Emotion Measures Questionnaire
- Illness Cognition (IC) Scale
- (and 16 more...)
|
97 |
All |
13 Years to 24 Years (Child, Adult) |
NCT02624193 |
NA_00093335
1R01AT007888 |
|
April 2013 |
September 2019 |
September 2019 |
December 8, 2015 |
January 26, 2018 |
|
- University of Maryland Medical Center
Baltimore, Maryland, United States - Johns Hopkins Harriet Lane Clinic
Baltimore, Maryland, United States
|
| 25 |
NCT01154296 |
Completed
Has Results |
HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S. |
- HIV/AIDS
- Sexually Transmitted Infections
|
- Behavioral: RESPECT-2 Counseling
|
Interventional |
Not Applicable |
- Columbia University
- National Institute on Drug Abuse (NIDA)
- University of Pittsburgh
- (and 9 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Screening
|
- STI Incidence
- Sexual Risk Behavior -- # of Sex Acts
- Sexual Risk Behavior -- # of Unprotected Sex Acts
- (and 3 more...)
|
5012 |
All |
18 Years and older (Adult, Senior) |
NCT01154296 |
AAAK3153
1RC2DA028973-01 |
Aware |
April 2010 |
July 2011 |
February 2012 |
June 30, 2010 |
September 29, 2014 |
September 29, 2014 |
- Los Angeles Gay & Lesbian Center
Los Angeles, California, United States - San Francisco Department of Public Health
San Francisco, California, United States - Whitman-Walker Clinic
Washington, District of Columbia, United States - (and 6 more...)
|
| 26 |
NCT02961751 |
Recruiting |
Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrheaoe |
|
|
Interventional |
Not Applicable |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The proportion of subjects infected with gyrA serine 91 genotype N. gonorrhoeae with microbiological cure.
- The proportion of subjects infected with gyrA serine 91 genotype N. gonorrhoeae identified by gyrA gene PCR who have ciprofloxacin-susceptible N. gonorrhoeae as identified by culture-based antimicrobial susceptibility testing.
- The proportion of subjects infected with gyrA serine 91 genotype N. gonorrhoeae with microbiological cure at each male or female urogenital tract)
- (and 2 more...)
|
257 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02961751 |
15-0090
HHSN272201300014I |
|
October 19, 2016 |
October 15, 2018 |
November 15, 2018 |
November 11, 2016 |
January 29, 2018 |
|
- AIDS Healthcare Foundation Wellness Center - Hollywood
Los Angeles, California, United States - Los Angeles Lesbian Gay Bisexual/Transgender Center
Los Angeles, California, United States - University of California, San Diego - Antiviral Research Center
San Diego, California, United States - (and 6 more...)
|
| 27 |
NCT00385567 |
Terminated |
A Trial of PEHRG214 in HIV-Infected Patients |
|
|
Interventional |
Phase 2 |
- Virionyx Corporation Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Decrease in viral load >= 1.0 log10 at 16 weeks
- Positive changes in CD4 count, weight, and Karnofsky Performance Score at 16 weeks
- Improvement in quality of life as determined monthly, using the MOS-HIV Health Survey
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT00385567 |
HRG2 |
|
January 2007 |
September 2008 |
September 2008 |
October 9, 2006 |
August 26, 2010 |
|
- L.A. Gay & Lesbian Center
Los Angeles, California, United States - University of Miami School of Medicine - AIDS Clinical Research Unit
Miami, Florida, United States - Northstar Healthcare
Chicago, Illinois, United States - (and 4 more...)
|
| 28 |
NCT00665561 |
Active, not recruiting |
Prospective Observational Epidemiologic Study of Maraviroc's Safety |
- Human Immunodeficiency Virus
|
- Drug: Maraviroc along with an optimized background antiretroviral drug regimen
- Drug: Optimized background antiretroviral drug regimen without maraviroc
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- CDC Category C AIDS defining infections, Viral encephalitis, Rhabdomyolysis, Liver failure, Liver related deaths
- All Malignancies (AIDS defining and non-AIDS defining), Myocardial ischemia or infarction, All cause mortality
- There are no Secondary Outcomes for this study.
|
2454 |
All |
18 Years and older (Adult, Senior) |
NCT00665561 |
A4001067
2007-006148-24
POEM |
POEM |
March 31, 2008 |
February 26, 2019 |
February 26, 2019 |
April 24, 2008 |
January 31, 2018 |
|
- Health Services Center
Hobson City, Alabama, United States - AAC/Davis Clinic
Huntsville, Alabama, United States - Alabama Infectious Diseases Center
Huntsville, Alabama, United States - (and 264 more...)
|
| 29 |
NCT03227861 |
Active, not recruiting |
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care |
|
- Drug: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
|
Interventional |
Phase 3 |
- Janssen Scientific Affairs, LLC
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than (<) 50 Copies per Milliliter (Copies/mL) at Week 48
- Change From Baseline in log10 HIV-1 RNA Viral Load at Weeks 2, 4, 8, 12, 24, 36, and 48
- Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24
- (and 22 more...)
|
109 |
All |
18 Years and older (Adult, Senior) |
NCT03227861 |
CR108345
TMC114FD2HTX3002 |
|
July 31, 2017 |
December 31, 2018 |
December 31, 2018 |
July 24, 2017 |
February 28, 2018 |
|
- Spectrum Medical Group
Phoenix, Arizona, United States - The Office of Franco Felizarta, MD
Bakersfield, California, United States - Jeffrey Goodman Clinic - DBA Los Angeles Gay and Lesbian Center
Los Angeles, California, United States - (and 13 more...)
|
| 30 |
NCT00377169 |
Completed |
Collection of Blood Samples From SMART Study Participants for Future Genetic Studies |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- Community Programs for Clinical Research on AIDS
|
NIH / Other |
|
|
3261 |
All |
13 Years and older (Child, Adult, Senior) |
NCT00377169 |
CPCRA 065H
SMART |
|
|
January 2006 |
January 2006 |
September 15, 2006 |
November 1, 2016 |
|
- AltaMed Health Services Corporation
Los Angeles, California, United States - Los Angeles Gay & Lesbian Community Service Center
Los Angeles, California, United States - VA Greater Los Angeles Healthcare System
Los Angeles, California, United States - (and 39 more...)
|
| 31 |
NCT00390780 |
Completed
Has Results |
Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients |
|
- Drug: miconazole Lauriad
- Drug: Clotrimazole
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale
- Clinical Cure at Day 7 (Using Murray Scoring Scale)
- Clinical Success at Test-of-cure Visit (Day 17-22) (Using Murray Scoring Scale)
- (and 10 more...)
|
578 |
All |
18 Years and older (Adult, Senior) |
NCT00390780 |
BA/2004/01/04 |
|
July 2006 |
December 2007 |
January 2008 |
October 20, 2006 |
September 16, 2013 |
August 29, 2013 |
- University of Alabama, Department of diagnostic Sciences School of Dentistry
Birmingham, Alabama, United States - L.A. Gay & Lesbian center, Health & Mental, health services
Los Angeles, California, United States - East Bay AIDS Center
Oakland, California, United States - (and 24 more...)
|
| 32 |
NCT01818596 |
Active, not recruiting
Has Results |
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment |
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24
- Change From Baseline in eGFR Calculated by the Chronic Kidney Disease Epidemiology Collaboration Method Based on Cystatin C (eGFR_CKD-EPI,cysC) at Week 24
- Change From Baseline in eGFR Calculated by the CKD-EPI Method Based on Serum Creatinine (eGFR_CKD-EPI,Creatinine) at Week 24
- (and 15 more...)
|
252 |
All |
18 Years and older (Adult, Senior) |
NCT01818596 |
GS-US-292-0112
2013-000516-25 |
|
March 27, 2013 |
July 31, 2014 |
September 2018 |
March 26, 2013 |
March 21, 2018 |
February 18, 2016 |
- Maricopa Integrated Health System - McDowell Clinic
Phoenix, Arizona, United States - Spectrum Medical Group
Phoenix, Arizona, United States - Pueblo Family Physicians
Phoenix, Arizona, United States - (and 114 more...)
|
| 33 |
NCT00027352 |
Completed |
A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study) |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Time Perspective: Prospective
|
|
6000 |
All |
13 Years and older (Child, Adult, Senior) |
NCT00027352 |
CPCRA 065
SMART |
|
|
|
|
December 5, 2001 |
November 25, 2009 |
|
- Kaiser Permanente-Fremont/Hayward Medical Centers
Fremont, California, United States - AIDS Healthcare Foundation
Los Angeles, California, United States - Los Angeles Gay and Lesbian Community Service Ctr
Los Angeles, California, United States - (and 220 more...)
|
| 34 |
NCT00107679 |
Completed |
A Study of Anal Cancer Development in HIV Infected People |
- HIV Infections
- Anus Neoplasms
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Time Perspective: Prospective
|
- Time to high-grade anal dysplasia or anal cancer
- Time to anal cancer
- time to low-grade or high-grade anal dysplasia
- (and 6 more...)
|
560 |
All |
13 Years and older (Child, Adult, Senior) |
NCT00107679 |
CPCRA 065G
SMART
10117 |
|
February 2005 |
March 2006 |
March 2006 |
April 7, 2005 |
April 17, 2014 |
|
- LA Gay & Lesbian Community Service Ctr., Lamba Med. Group CRS
Los Angeles, California, United States - Castro-Mission Health Ctr. CRS
San Francisco, California, United States - Univ. of Colorado Health Science Ctr. CRS
Denver, Colorado, United States - (and 10 more...)
|
| 35 |
NCT01108510 |
Completed
Has Results |
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults |
|
- Drug: COBI
- Drug: RTV
- Drug: ATV
- (and 3 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144
- (and 5 more...)
|
698 |
All |
18 Years and older (Adult, Senior) |
NCT01108510 |
GS-US-216-0114
2009-016759-22 |
|
April 2010 |
November 2011 |
April 2015 |
April 22, 2010 |
May 23, 2016 |
October 28, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Spectrum Medical Group
Phoenix, Arizona, United States - Health for Life Clinic PLLC
Little Rock, Arkansas, United States - (and 131 more...)
|
| 36 |
NCT01106586 |
Completed
Has Results |
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults |
|
- Drug: Stribild
- Drug: ATV
- Drug: Ritonavir
- (and 5 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48
- The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 96
- The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 144
- (and 4 more...)
|
708 |
All |
18 Years and older (Adult, Senior) |
NCT01106586 |
GS-US-236-0103 |
|
April 2010 |
September 2011 |
September 2014 |
April 20, 2010 |
November 11, 2015 |
October 22, 2012 |
- Spectrum Medical Group
Phoenix, Arizona, United States - Health for Life Clinic PLLC
Little Rock, Arkansas, United States - AHF Research Center
Beverly Hills, California, United States - (and 143 more...)
|
| 37 |
NCT01095796 |
Completed
Has Results |
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults |
|
- Drug: Stribild
- Drug: Atripla
- Drug: Stribild Placebo
- Drug: Atripla Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48
- The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 96
- The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 144
- (and 4 more...)
|
707 |
All |
18 Years and older (Adult, Senior) |
NCT01095796 |
GS-US-236-0102 |
|
March 2010 |
August 2011 |
September 2014 |
March 30, 2010 |
November 11, 2015 |
October 22, 2012 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Spectrum Medical Group
Phoenix, Arizona, United States - Health for Life Clinic PLLC
Little Rock, Arkansas, United States - (and 99 more...)
|
| 38 |
NCT01309243 |
Completed
Has Results |
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults |
|
- Drug: FTC/RPV/TDF
- Drug: EFV/FTC/TDF
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
- Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
- Change From Baseline in CD4 Cell Count at Week 48
- (and 7 more...)
|
799 |
All |
18 Years and older (Adult, Senior) |
NCT01309243 |
GS-US-264-0110 |
|
February 2011 |
September 2012 |
February 2014 |
March 7, 2011 |
February 25, 2015 |
November 27, 2013 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Spectrum Medical Group
Phoenix, Arizona, United States - AHF Research Center
Beverly Hills, California, United States - (and 148 more...)
|
| 39 |
NCT02755350 |
Unknown † |
Introducing PrEP Into HIV Combination Prevention - Kenya |
|
|
Interventional |
Not Applicable |
- LVCT Health
- Bill and Melinda Gates Foundation
- Sex Workers Outreach Project
- (and 16 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of young women, female sex workers and men who have sex with men correctly identified as being at high risk of HIV, in need of and willing to take PrEP.
- Proportion of men who have sex with men, female sex workers and young women at high risk of HIV enrolled into a HIV combination prevention intervention package that includes PrEP.
- Number of participants adhering to oral PrEP as measured using the MEMS cap and MedAmigo system.
- (and 5 more...)
|
2100 |
All |
15 Years and older (Child, Adult, Senior) |
NCT02755350 |
NON-SSC NO. 456
OPP1104919 |
IPCP-Kenya |
August 2015 |
November 2016 |
April 2017 |
April 28, 2016 |
April 28, 2016 |
|
- LVCT Health
Nairobi, Kenya
|
Create an RSS feed from your search for:
Download the search results for: